Structure via PubChem · Public domain (PubChem)
memantina
Sign in to saveAlso known as 3,5-dimethyl-1-adamantanamine, 1,3-dimethyl-5-adamantanamine, 3,5-dimethyl-1-aminoadamantane, 3,5-dimethyltricyclo[3.3.1.1(3,7)]decan-1-amine, 1-amino-3,5-dimethyladamantane, 1,3-dimethylaminoadamantane
grupo de estereoisómeros
Chemical data
- Formula
- C12H21N
- Molecular weight
- 179.3 g/mol
- IUPAC name
- 3,5-dimethyladamantan-1-amine
- SMILES
- CC12CC3CC(C1)(CC(C3)(C2)N)C
- InChIKey
- BUGYDGFZZOZRHP-UHFFFAOYSA-N
- XLogP
- 3.3
- Polar surface area
- 26 Ų
- H-bond donors
- 1
- H-bond acceptors
- 1
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2002
- Admin. routes
- oral
- Indications
- autism spectrum disorder, nicotine dependence, autism, pain
via ChEMBL · EBI
Research
5,145 papers- Mechanism of action of memantine.Current opinion in pharmacology · 2006
- Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias.Ideggyogyaszati szemle · 2021
- Memantine.Drugs & aging · 2003
- Memantine: Updating a rare success story in pro-cognitive therapeutics.Neuropharmacology · 2024
- Memantine Derivatives as Multitarget Agents in Alzheimer's Disease.Molecules (Basel, Switzerland) · 2020
via PubMed
Described at
Memantine: a medicine to treat some types of dementia. - NHS
NHS medicines information on memantine – what it's used for, side effects, dosage and who can take it.
nhs.uk →Link to a page describing this subject · 2,355 chars · not written by Vinony
Wikidata facts
- Has part
- carbon
- Mass
- 179.1674
- Has use
- medication
Show 8 more facts
- Commons category
- Memantine
- medical condition treated
- Alzheimer's disease
- chemical formula
- C₁₂H₂₁N
- canonical SMILES
- CC12CC3CC(C1)(CC(C3)(C2)N)C
- World Health Organisation international non-proprietary name
- memantine
- defined daily dose
- 40
- subject has role
- dopaminergic
- described at URL
- www.healthline.com/health/drugs/memantine-oral-tablet
Sources (7)
via Wikidata · CC0
Article · Español
La memantina es un fármaco antagonista no competitivo del receptor NMDA (N-metil-D-aspartato), con afinidad moderada, fuertemente dependiente de voltaje y con cinéticas de bloqueo y desbloqueo rápidas. El bloqueo del receptor NMDA modula los efectos de la elevación patológica del glutamato que es dañino para la función neuronal. De esta forma la memantina reduce la excitotoxicidad inducida por el NMDA, pero aun así permite la activación del receptor para las funciones fisiológicas. Se utiliza para el tratamiento de varias enfermedades neuropsiquiátricas, entre ellas la enfermedad de Alzheimer. La memantina ha demostrado tener un efecto beneficioso en el tratamiento de la enfermedad de Alzheimer moderada a severa. No obstante, en la enfermedad de Alzheimer leve y moderada no se ha demostrado fehacientemente su utilidad.
Abstract from DBpedia / Wikipedia · CC BY-SA